Twist Bioscience reveals initial Bundibugyo outbreak genomes while stock holds above key support

Twist Bioscience reveals initial Bundibugyo outbreak genomes while stock holds above key support
Twist Bioscience down 1.09% today

Twist Bioscience reports initial genomes from the May 2026 Bundibugyo Virus Disease Outbreak in the Democratic Republic of the Congo and Uganda.

The announcement concerns the Ebolavirus, specifically the Bundibugyo ebolavirus. Details are available on Virological.

Highlights

  • TWST maintains persistent bullish momentum across all time frames, trading well above major support levels at $64–$61.50.
  • Despite overbought indicators and divergent short-term signals, trend strength remains intact and buyers retain control.
  • Next week’s expected range is $66–$74, with a breakout above $74 favoring further gains and support near $66 crucial for downside risk.

Bullish positioning sustained as key support and resistance areas tighten

TWST is currently at $69.28, which sits well above the MA-20 ($61.48), MA-50 ($57.72), and MA-200 ($41.15), signaling persistent bullish momentum across short, medium, and long-term trends. The Ichimoku Kijun on D1 stands at $64.27, acting as immediate support beneath the current price; near-term support is found at $64.27 (Kijun) and $61.48 (MA-20), while key support sits at $57.72 (MA-50) and $52.00 (MA-100); resistance levels are at $71.13 (MA-5/cluster near-term) and $80.50 (recent weekly high).

Uptrend momentum persists as overbought risks and divergence surface

Momentum remains strong with MACD on D1 in "Buy" mode and ADX on D1 at 21.60, confirming an established trend, while the D1 RSI at 62.88 signals bullish but not extreme conditions. However, Stoch RSI is neutral, and CCI is in "Buy" territory but approaching overbought levels, while BBP on D1 is flagged as "Overbought", suggesting buyer dominance may be stretched in the short term. The AO supports the uptrend, but several oscillators point to building overbought risk and some divergence among signals. TWST is trading at $69.28, virtually flat compared to the previous week’s close of $69.22, indicating a 0.20% gain over the past week. The price is currently at the very bottom of the weekly range, with weekly volatility standing at 18.26%. The week has seen a steady retreat from its earlier highs, with the price currently pinned at support.

High upside probability as price consolidates near top of range

For the coming week, the expected range for TWST is $66.00–$74.00, normalized around the current price in line with recent volatility and confirmed by the technical profile; this places the action toward the higher end of its 52-week corridor of $23.30–$80.50. The probability of a further price increase is very high (more than 80%), with a significantly lower chance of a decline. The baseline scenario sees TWST consolidating between $66 and near-term resistance at $74. Bullish momentum could fuel a breakout above $74 if buyer pressure persists and momentum signals strengthen. Conversely, a bearish scenario would emerge on a break below $66, exposing key supports toward $61.50–$64.00.

Earlier, analysts noted that Twist Bioscience maintained a strong bullish trend, bolstered by positive momentum indicators despite short-term volatility risks. This article builds on that outlook, urging investors to monitor current price action for signs of sustained consolidation or a potential breakout that could define the prevailing scenario in the sessions ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.